GlobeImmune (United States)
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for GlobeImmune (United States), United States, covering academic research published from 2000 to 2025. Read More.
Open Access Percentage
37%
Total
Publications
84
Total Open
Publications
31
Total
Citations
3.7K
Open Access
Percentage
37%
Total
Publications
84
Total Open
Publications
31
Total
Citations
3.7K
Breakdown
Publisher Open
17%
Both
14%
Other Platform Open
6%
Closed
63%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 35%
9
Hybrid 19%
5
No Guarantees 46%
12
Other Platform Open
Domain 71%
12
Institution 24%
4
Preprint 24%
4
Public 6%
1
Other Internet 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 12 |
Research Square | Preprint | 3 |
doaj.org OAI-PMH Repository | Institution | 2 |
Yonsei University | Institution | 1 |
University of Modena and Reggio Emilia | Institution | 1 |
Royal Netherlands Academy of Arts and Sciences | Institution | 1 |
Figshare | Public | 1 |
Erasmus University Rotterdam | Institution | 1 |
bioRxiv | Preprint | 1 |